Congress has cut federal funding for public media — a $3.4 million loss for LAist. We count on readers like you to protect our nonprofit newsroom. Become a monthly member and sustain local journalism.
Walk-In Assessments And Telehealth Are Now Options For COVID Treatment For High Risk Angelenos
Molnupiravir, an antiviral drug to treat mild-to-moderate COVID-19, is one of the medications now being used.
(
Courtesy Merck
)
High-risk patients with COVID symptoms can now walk into dozens of clinics and county testing sites in L.A. and, if they test positive, walk out with a free course of COVID treatment pills.
There are currently 39 community sites, 20 CVS sites and 11 Walgreens Test-to-Treat sites in the county. You can find the location closest to you here.
Angelenos can already get the treatment prescribed by their doctors, but Test-to-Treat is an additional pipeline for COVID pills that intends to streamline the process for high-risk patients who need to start the treatment quickly for it to work. But it is limited by the requirement to have a prescriber on-site, which most pharmacies don't have.
(
Courtesy of the L.A. County Dept. of Public Health
)
Support for LAist comes from
To help address the gaps, telehealth visits are also now an option for residents who can’t go to the physical sites or don’t have one close by, county public health director Barbara Ferrer said at her weekly briefing.
Residents can call (833) 540-0473 seven days a week between 8 a.m. and 8:30 p.m. Call center staff will answer questions and connect patients to services as needed.
“The Department of Public Health telehealth providers are clinicians that are available seven days a week to screen patients for eligibility and determine which medication, if any, would be appropriate for that patient,” Ferrer said. “Medications are then shipped to the patient's home overnight. All of this is at no charge.”
Two COVID treatment pill options are currently authorized by the FDA — Paxlovid from Pfizer and Molnupiravir from Merck and Ridgeback Pharmaceuticals. The pills are antivirals, which means they stop the virus from duplicating in the body.
- Paxlovid (available for anyone 12 and older weighing more than 88 pounds) and
- Molnupiravir (available for adults 18 and older) are oral therapeutics that must be taken within five days of the first COVID-19 symptoms and require a prescription from a healthcare provider.
For both medications, "it's really important to start treatment within three to five days or so of the onset of infection,” Ferrer said. “They work best if there’s very little time between when you get an assessment by a provider and the time you get the medicine."
Pfizer's Paxlovid is considered highly effective, reducing the risks of hospitalization by nearly 90%, but it can interfere with many commonly prescribed drugs and cause health problems if the drug dosages aren't adjusted.
Merck's molnupiravir is less effective — cutting the risks of severe COVID by around 30%, according to data reviewed by the FDA — and it comes with reproductive risks.
Support for LAist comes from
Ferrer said the county health department is working to increase awareness and access to COVID therapeutics, calling them “critical” for county residents at high risk of contracting the virus.
“These treatments can help prevent serious illness, hospitalization or death,” Ferrer said.
You can find all of our COVID-related health coverage here.
As Editor-in-Chief of our newsroom, I’m extremely proud of the work our top-notch journalists are doing here at LAist. We’re doing more hard-hitting watchdog journalism than ever before — powerful reporting on the economy, elections, climate and the homelessness crisis that is making a difference in your lives. At the same time, it’s never been more difficult to maintain a paywall-free, independent news source that informs, inspires, and engages everyone.
Simply put, we cannot do this essential work without your help. Federal funding for public media has been clawed back by Congress and that means LAist has lost $3.4 million in federal funding over the next two years. So we’re asking for your help. LAist has been there for you and we’re asking you to be here for us.
We rely on donations from readers like you to stay independent, which keeps our nonprofit newsroom strong and accountable to you.
No matter where you stand on the political spectrum, press freedom is at the core of keeping our nation free and fair. And as the landscape of free press changes, LAist will remain a voice you know and trust, but the amount of reader support we receive will help determine how strong of a newsroom we are going forward to cover the important news from our community.
Please take action today to support your trusted source for local news with a donation that makes sense for your budget.
Thank you for your generous support and believing in independent news.
Chip in now to fund your local journalism
(
LAist
)
Trending on LAist
-
The new ordinance applies to certain grocers operating in the city and has led to some self-checkout lanes to shutter. -
Children asked to waive right to see a judge in exchange for $2,500 -
There’s still a lot to be determined as the refinery, which supplies about one-fifth of Southern California's vehicle fuels, works to restore production and as data is collected. -
The FCC voted to end E-Rate discounts for library hotspot lending and school bus Wi-Fi. -
About half the Pacific Airshow’s 2025 lineup has been grounded because of the federal government shutdown. -
USC says it’s reviewing the letter also sent to eight other prestigious schools nationwide. California's governor vowed that any California universities that sign will lose state funding.
Best of LAist